DBVT DBV TECHNOLOGIES SA US FDA Inspections 8-K Filing 2023 - Clinical Trial Announcement DBV Technologies announced the screening of the first patient in a Phase 3 clinical trial for peanut allergy in children aged 4-7 years old.Get access to all SEC 8-K filings of the DBV TECHNOLOGIES SA